Review

mcl1 (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech mcl1

Knockdown of CCT2 inhibits STAT3 signaling activation in hepatocellular carcinoma cells. The protein levels of STAT3, p-STAT3, <t>MCL1,</t> MMP2 and SOX2 in (A) Huh-7 and (B) HCCLM3 cells were measured by western blotting. The protein levels of (C) p-STAT3, (D) MCL1, (E) MMP2 and (F) SOX2 in subcutaneous tumor tissue were detected by immunohistochemical staining. *P<0.05, **P<0.01 vs. sh-NC. CCT2, chaperonin containing TCP1 subunit 2; sh, short hairpin; NC, negative control; p, phosphorylated; MCL1, myeloid cell leukemia sequence 1; SOX2, SRY-box transcription factor 2.

Mcl1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 194 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mcl1/MCL1+Antibody/pmc12983126-120-11-25
Average 96 stars, based on 194 article reviews

mcl1 - by Bioz Stars, 2026-09

96/100 stars

Images

1) Product Images from "Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation"

Article Title: Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation

Journal: Oncology Reports

doi: 10.3892/or.2026.9086

Knockdown of CCT2 inhibits STAT3 signaling activation in hepatocellular carcinoma cells. The protein levels of STAT3, p-STAT3, MCL1, MMP2 and SOX2 in (A) Huh-7 and (B) HCCLM3 cells were measured by western blotting. The protein levels of (C) p-STAT3, (D) MCL1, (E) MMP2 and (F) SOX2 in subcutaneous tumor tissue were detected by immunohistochemical staining. *P<0.05, **P<0.01 vs. sh-NC. CCT2, chaperonin containing TCP1 subunit 2; sh, short hairpin; NC, negative control; p, phosphorylated; MCL1, myeloid cell leukemia sequence 1; SOX2, SRY-box transcription factor 2.

Figure Legend Snippet: Knockdown of CCT2 inhibits STAT3 signaling activation in hepatocellular carcinoma cells. The protein levels of STAT3, p-STAT3, MCL1, MMP2 and SOX2 in (A) Huh-7 and (B) HCCLM3 cells were measured by western blotting. The protein levels of (C) p-STAT3, (D) MCL1, (E) MMP2 and (F) SOX2 in subcutaneous tumor tissue were detected by immunohistochemical staining. *P<0.05, **P<0.01 vs. sh-NC. CCT2, chaperonin containing TCP1 subunit 2; sh, short hairpin; NC, negative control; p, phosphorylated; MCL1, myeloid cell leukemia sequence 1; SOX2, SRY-box transcription factor 2.

Techniques Used: Knockdown, Activation Assay, Western Blot, Immunohistochemical staining, Staining, Negative Control, Sequencing

other:

Article Title: FOXO3 upregulates and activates GSDME to trigger myeloma cell pyroptosis
Article Snippet: Antibodies against FOXO3 (Cat. #10849-1-AP), BAX (Cat. #50599-2-lg), BCL2 (Cat. #26593-1-AP), BCL2L1 (Bcl-xL, Cat. #10783-1-AP), MCL1 (Cat. #16225-1-AP) and BNIPL (Cat. #13262-1-AP) were obtained from Proteintech Group (Wuhan, China).

Article Title: Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
Article Snippet: MCL1 , Proteintech , 16225-1-AP; RRID: AB_2143977.

Article Title: Therapeutic targeting SPI1 in combination with erastin promotes ferroptosis in ccRCC.
Article Snippet: The following antibodies were used forWestern blot analysis: SPI1 (55100- 1-AP, Proteintech), MCL1 (16225-1-AP, Proteintech, 1:1000), H3K27me3 (9733S, CST, 1:1000), Bcl-2 (68103-1-Ig, Proteintech, 1:1000), ACSL4 (22401-1-AP, Proteintech, 1:1000), EZH2 (21800-1-AP, Proteintech, 1:1000), β-ACTIN (66009-1-Ig, Proteintech, 1:2000) and GAPDH (60004- 1-Ig, Proteintech, 1:2000).

Blocking Assay:

Article Title: Neutrophil-derived exosomes inhibit gastric cancer progression via miR-101-3p-mediated suppression of MCL1.
Article Snippet: Samples (20 μg/lane) were separated on 10% SDS-PAGE gels (Vazyme; China) and transferred to PVDF membranes. .. After blocking with 5% non-fat milk, membranes were incubated overnight with primary antibodies against PARP, Cleaved PARP, Caspase3, Cleaved Caspase3, CD9, CD63, TSG101, Calnexin (Cell Signaling Technology; USA), EZH2, MCL1, c-Myc, and β-actin (Proteintech; China). .. Membranes were washed with TBST, probed with HRP-conjugated secondary antibodies (Bioworld; USA), and visualized using ECL substrate (Thermo Fisher Scientific; USA) on a Tanon 5200 system. β-actin was used as the loading control.

Article Title: Neutrophil-derived exosomes inhibit gastric cancer progression via miR-101-3p-mediated suppression of MCL1
Article Snippet: Samples (20 μg/lane) were separated on 10% SDS-PAGE gels (Vazyme; China) and transferred to PVDF membranes. .. After blocking with 5% non-fat milk, membranes were incubated overnight with primary antibodies against PARP, Cleaved PARP, Caspase3, Cleaved Caspase3, CD9, CD63, TSG101, Calnexin, GM130, APOA1 (Cell Signaling Technology; USA), EZH2, MCL1, c-Myc, and β-actin (Proteintech; China). .. Membranes were washed with TBST, probed with HRP-conjugated secondary antibodies (Bioworld; USA), and visualized using ECL substrate (Thermo Fisher Scientific; USA) on a Tanon 5200 system. β-actin was used as the loading control.

Incubation:

Image Search Results

PROTAC Mcl-1 Degrader-1 reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.

Journal: Current Issues in Molecular Biology

Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

doi: 10.3390/cimb48070733

Figure Lengend Snippet: PROTAC Mcl-1 Degrader-1 reduced the viability of HT-29 and COLO-205 cells. ( A ) Molecular structure of PROTAC Mcl-1 Degrader-1 (The pink end of the PROTAC molecule binds to the target protein, while the blue end binds to the E3 ligase). Cell viability of ( B , C ) Colorectal cancer cell lines (HT-29/COLO-205) was determined by WST-8 assay after 24 and 48 h of treatment with PROTAC Mcl-1 Degrader-1. (n = 3 replicates). ( D , E ) In a 48 h combination therapy where trametinib remained stable at 1 µM and PROTAC Mcl-1 Degrader-1 doses varied, it was shown to effectively reduce the viability of ( D ) HT-29 and ( E ) COLO-205 cells. ( F ) Western blot analysis showed a decrease in MCL-1 protein levels in PROTAC Mcl-1 Degrader-1 colorectal cancer cell lines. Three repetitions were performed in each group. ( G ) Mcl-1 and Bcl-2 protein expressions were statistically evaluated. The results were obtained by one-way ANOVA test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ‘ns’ means not significant.

Article Snippet: PROTAC Mcl-1 Degrader-1 (compound C3 ) (Catalog number: HY-125877) and Trametinib (Catalog number: HY-10999) were purchased from MedChem Express (Township, NJ, USA) and dissolved in DMSO.

Techniques: Western Blot

PROTAC Mcl-1 Degrader-1 and Trametinib affect the proliferation of HT-29 and COLO-205 cells. ( A – C ) Simultaneous results obtained by Xcelligence Real-Time Proliferation assay after 48 h of treatment of HT-29 cells with ( A ) PROTAC Mcl-1 Degrader-1 and ( B ) Trametinib. Doses are represented by the same colors in the graph. ( D – F ) Proliferation results of COLO-205 cell line after 48 h of single and combined treatment with ( D ) PROTAC Mcl-1 Degrader-1 and ( E ) Trametinib, respectively. In combination, a dose of 1 µM Trametinib was used, and treatment was applied with variable doses of PROTAC Mcl-1 Degrader-1.

Journal: Current Issues in Molecular Biology

Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

doi: 10.3390/cimb48070733

Figure Lengend Snippet: PROTAC Mcl-1 Degrader-1 and Trametinib affect the proliferation of HT-29 and COLO-205 cells. ( A – C ) Simultaneous results obtained by Xcelligence Real-Time Proliferation assay after 48 h of treatment of HT-29 cells with ( A ) PROTAC Mcl-1 Degrader-1 and ( B ) Trametinib. Doses are represented by the same colors in the graph. ( D – F ) Proliferation results of COLO-205 cell line after 48 h of single and combined treatment with ( D ) PROTAC Mcl-1 Degrader-1 and ( E ) Trametinib, respectively. In combination, a dose of 1 µM Trametinib was used, and treatment was applied with variable doses of PROTAC Mcl-1 Degrader-1.

Techniques: Proliferation Assay

Effect of PROTAC Mcl-1 Degrader-1 on the migratory ability of colorectal cancer cells. ( A ) Wound healing assay was performed under a microscope (original magnification 4×) using an inverted microscope (500 µm scale bar) and images were taken at 0, 24 and 48 time intervals after treatment with different doses of PROTAC Mcl-1 Degrader-1 in HT-29 and ( B ) COLO-205 cell lines. ( C , D ) Wound closure analyses of HT-29 and COLO-205 cells were measured using PROTAC Mcl-1 Degrader-1 and microscopic images taken at 24 (black bars) and 48 (red bars) time intervals. Results are presented as mean ± standard deviation (n = 3/group). Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ** p < 0.01; ns = not significant.

Journal: Current Issues in Molecular Biology

Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

doi: 10.3390/cimb48070733

Figure Lengend Snippet: Effect of PROTAC Mcl-1 Degrader-1 on the migratory ability of colorectal cancer cells. ( A ) Wound healing assay was performed under a microscope (original magnification 4×) using an inverted microscope (500 µm scale bar) and images were taken at 0, 24 and 48 time intervals after treatment with different doses of PROTAC Mcl-1 Degrader-1 in HT-29 and ( B ) COLO-205 cell lines. ( C , D ) Wound closure analyses of HT-29 and COLO-205 cells were measured using PROTAC Mcl-1 Degrader-1 and microscopic images taken at 24 (black bars) and 48 (red bars) time intervals. Results are presented as mean ± standard deviation (n = 3/group). Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ** p < 0.01; ns = not significant.

Techniques: Wound Healing Assay, Microscopy, Inverted Microscopy, Standard Deviation, Comparison, Software

The combination of PROTAC Mcl-1 Degrader-1 and Trametinib did not lead to a statistically significant change in cell migration. ( A , B ) Colorectal cancer cells HT-29 and COLO-205 were treated with a combination of PROTAC Mcl-1 Degrader-1 and Trametinib. Trametinib dose was kept constant at 1 µM, while PROTAC Mcl-1 Degrader-1 doses were varied. Cell migration analysis was performed after treatment. Migration capabilities at 0, 24, and 48 h were visualized under a microscope. ( C , D ) Graphical analysis of wound closure was performed to determine the migratory ability of cells. The analysis was performed by comparing the 24 and 48 h treatments with the control group (ns = not significant).

Journal: Current Issues in Molecular Biology

Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

doi: 10.3390/cimb48070733

Figure Lengend Snippet: The combination of PROTAC Mcl-1 Degrader-1 and Trametinib did not lead to a statistically significant change in cell migration. ( A , B ) Colorectal cancer cells HT-29 and COLO-205 were treated with a combination of PROTAC Mcl-1 Degrader-1 and Trametinib. Trametinib dose was kept constant at 1 µM, while PROTAC Mcl-1 Degrader-1 doses were varied. Cell migration analysis was performed after treatment. Migration capabilities at 0, 24, and 48 h were visualized under a microscope. ( C , D ) Graphical analysis of wound closure was performed to determine the migratory ability of cells. The analysis was performed by comparing the 24 and 48 h treatments with the control group (ns = not significant).

Techniques: Migration, Microscopy, Control

Effect of PROTAC Mcl-1 Degrader-1 on cell count in colorectal cancer. ( A ) Flow cytometric analysis of the preservation of HT-29 and COLO-205 cell counts after 48 h of maintenance with PROTAC Mcl-1 Degrader-1 (n = 3). ( B , C ) Statistical analysis of the percentage cell counts of HT-29 and COLO-205 cells. Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ns = not significant.

Journal: Current Issues in Molecular Biology

Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

doi: 10.3390/cimb48070733

Figure Lengend Snippet: Effect of PROTAC Mcl-1 Degrader-1 on cell count in colorectal cancer. ( A ) Flow cytometric analysis of the preservation of HT-29 and COLO-205 cell counts after 48 h of maintenance with PROTAC Mcl-1 Degrader-1 (n = 3). ( B , C ) Statistical analysis of the percentage cell counts of HT-29 and COLO-205 cells. Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ns = not significant.

Techniques: Cell Characterization, Preserving, Comparison, Software

Combination treatment with PROTAC Mcl-1 Degrader-1 and Trametinib for 48 h showed a more pronounced effect on cell cycle distribution in HT-29 cells compared to COLO-205 cells. ( A ) A graph of the cell cycle percentage of HT-29 and COLO-205 cells was plotted after the combination. ( B , C ) As shown in the statistical analysis, an effect was observed in the S and G2/M phases in the HT-29 cell line, while no significant effect was statistically demonstrated in the COLO-205 cell line. Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ns = not significant.

Journal: Current Issues in Molecular Biology

Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

doi: 10.3390/cimb48070733

Figure Lengend Snippet: Combination treatment with PROTAC Mcl-1 Degrader-1 and Trametinib for 48 h showed a more pronounced effect on cell cycle distribution in HT-29 cells compared to COLO-205 cells. ( A ) A graph of the cell cycle percentage of HT-29 and COLO-205 cells was plotted after the combination. ( B , C ) As shown in the statistical analysis, an effect was observed in the S and G2/M phases in the HT-29 cell line, while no significant effect was statistically demonstrated in the COLO-205 cell line. Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05; ns = not significant.

Techniques: Comparison, Software

The combination of PROTAC Mcl-1 Degrader-1 and Trametinib affected mitochondrial membrane potential. ( A ) HT-29 and COLO-205 cell lines were stained with JC-1 after treatment with PROTAC Mcl-1 Degrader-1 for 48 h and imaged under a fluorescence microscope (original magnification 20×). The yellow-orange fluorescence of JC-1 dimers was found in cell regions with high mitochondrial membrane potential, while the green fluorescence of JC-monomers was prevalent in cell regions with low mitochondrial membrane potential. ( B , C ) Percentage red/green fluorescence intensity plots showed that HT-29 and COLO-205 cells were converted to MMP in both cell lines after 48 h of treatment with PROTAC Mcl-1 Degrader-1, particularly at the final dose of 10 μM. ( D ) Cell lines treated with a combination of PROTAC Mcl-1 Degrader-1 and Trametinib at different 48 h doses were subjected to JC-1 staining. After staining (original magnification 20×), images were acquired under a fluorescence microscope. ( E , F ) Quantitative analysis of the transition from mitochondrial orange to green coloration between different combination treatment groups. The statistical value of this experiment was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns = not significant.

Journal: Current Issues in Molecular Biology

Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

doi: 10.3390/cimb48070733

Figure Lengend Snippet: The combination of PROTAC Mcl-1 Degrader-1 and Trametinib affected mitochondrial membrane potential. ( A ) HT-29 and COLO-205 cell lines were stained with JC-1 after treatment with PROTAC Mcl-1 Degrader-1 for 48 h and imaged under a fluorescence microscope (original magnification 20×). The yellow-orange fluorescence of JC-1 dimers was found in cell regions with high mitochondrial membrane potential, while the green fluorescence of JC-monomers was prevalent in cell regions with low mitochondrial membrane potential. ( B , C ) Percentage red/green fluorescence intensity plots showed that HT-29 and COLO-205 cells were converted to MMP in both cell lines after 48 h of treatment with PROTAC Mcl-1 Degrader-1, particularly at the final dose of 10 μM. ( D ) Cell lines treated with a combination of PROTAC Mcl-1 Degrader-1 and Trametinib at different 48 h doses were subjected to JC-1 staining. After staining (original magnification 20×), images were acquired under a fluorescence microscope. ( E , F ) Quantitative analysis of the transition from mitochondrial orange to green coloration between different combination treatment groups. The statistical value of this experiment was determined using one-way ANOVA and Tukey’s multiple comparison test (GraphPad Prism 10.0, GraphPad Software Inc.). ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns = not significant.

Techniques: Membrane, Staining, Fluorescence, Microscopy, Comparison, Software

PROTAC Mcl-1 Degrader-1 alone was associated with a partial increase in apoptotic cell populations. (Q1 LL (Control), Q1 UL (Necrosis), Q1 UR (Late apoptosis), Q1 LR (Early apoptosis). ( A ) After 48 h of PROTAC Mcl-1 Degrader-1 treatment of HT-29 and COLO-205 cells, Annexin V and PI-labeled cell apoptosis was analyzed by flow cytometry. ( B , C ) Statistical analysis of cells in ( B ) early and ( C ) late apoptosis phases of HT-29 cell line after treatment with PROTAC Mcl-1 Degrader-1. ( D , E ) Statistical analysis of COLO-205 cells in ( D ) early and ( E ) late apoptosis phases after treatment with PROTAC Mcl-1 Degrader-1. The obtained results were presented using mean ± standard deviation (n = 3/group). Statistical significance in the experiment was determined using one-way ANOVA and Tukey’s test for multiple comparisons (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05.

Journal: Current Issues in Molecular Biology

Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

doi: 10.3390/cimb48070733

Figure Lengend Snippet: PROTAC Mcl-1 Degrader-1 alone was associated with a partial increase in apoptotic cell populations. (Q1 LL (Control), Q1 UL (Necrosis), Q1 UR (Late apoptosis), Q1 LR (Early apoptosis). ( A ) After 48 h of PROTAC Mcl-1 Degrader-1 treatment of HT-29 and COLO-205 cells, Annexin V and PI-labeled cell apoptosis was analyzed by flow cytometry. ( B , C ) Statistical analysis of cells in ( B ) early and ( C ) late apoptosis phases of HT-29 cell line after treatment with PROTAC Mcl-1 Degrader-1. ( D , E ) Statistical analysis of COLO-205 cells in ( D ) early and ( E ) late apoptosis phases after treatment with PROTAC Mcl-1 Degrader-1. The obtained results were presented using mean ± standard deviation (n = 3/group). Statistical significance in the experiment was determined using one-way ANOVA and Tukey’s test for multiple comparisons (GraphPad Prism 10.0, GraphPad Software Inc.). * p < 0.05.

Techniques: Control, Labeling, Flow Cytometry, Standard Deviation, Software

The combination of PROTAC Mcl-1 Degrader-1 and trametinib was observed to be associated with an increase in apoptotic cell populations. (Q1 LL (Control), Q1 UL (Necrosis), Q1 UR (Late apoptosis), Q1 LR (Early apoptosis). ( A ) The degree of apoptosis in HT-29 and COLO-205 cells was monitored by flow cytometry after 48 h of exposure to a combination of PROTAC Mcl-1 Degrader-1 and Trametinib. Combination therapy was shown to be associated with a higher level of apoptosis compared to monotherapy. ( B , C ) Treatment of the HT-29 cell line with the combination of PROTAC Mcl-1 Degrader-1 and Trametinib showed increased early and late apoptosis graphs, indicating the stages of apoptosis, compared to the control group. ( D , E ) The outcome of combination therapy in the COLO-205 cell line shows a significant effect on early apoptosis in the early and late apoptosis graphs. Statistical analysis after combination therapy showed that the final dose of 1 µm Trametinib and 10 µm PROTAC Mcl-1 Degrader-1 increased early apoptosis by 23% and late apotosis by 8%, particularly in the COLO-205 cell line. The values are expressed as the mean ± SD (n = 3/group). Statistical significance was determined using one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01; ns = not significant.

Journal: Current Issues in Molecular Biology

Article Title: Targeted Degradation of MCL-1 by PROTAC Mcl-1 Degrader-1 Exhibits Antiproliferative and Antimigratory Effects and Triggers Mitochondria-Mediated Apoptosis in Colorectal Cancer

doi: 10.3390/cimb48070733

Figure Lengend Snippet: The combination of PROTAC Mcl-1 Degrader-1 and trametinib was observed to be associated with an increase in apoptotic cell populations. (Q1 LL (Control), Q1 UL (Necrosis), Q1 UR (Late apoptosis), Q1 LR (Early apoptosis). ( A ) The degree of apoptosis in HT-29 and COLO-205 cells was monitored by flow cytometry after 48 h of exposure to a combination of PROTAC Mcl-1 Degrader-1 and Trametinib. Combination therapy was shown to be associated with a higher level of apoptosis compared to monotherapy. ( B , C ) Treatment of the HT-29 cell line with the combination of PROTAC Mcl-1 Degrader-1 and Trametinib showed increased early and late apoptosis graphs, indicating the stages of apoptosis, compared to the control group. ( D , E ) The outcome of combination therapy in the COLO-205 cell line shows a significant effect on early apoptosis in the early and late apoptosis graphs. Statistical analysis after combination therapy showed that the final dose of 1 µm Trametinib and 10 µm PROTAC Mcl-1 Degrader-1 increased early apoptosis by 23% and late apotosis by 8%, particularly in the COLO-205 cell line. The values are expressed as the mean ± SD (n = 3/group). Statistical significance was determined using one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05; ** p < 0.01; ns = not significant.

Techniques: Control, Flow Cytometry, Comparison

Journal: Oncology Reports

Article Title: Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation

doi: 10.3892/or.2026.9086

Figure Lengend Snippet: Knockdown of CCT2 inhibits STAT3 signaling activation in hepatocellular carcinoma cells. The protein levels of STAT3, p-STAT3, MCL1, MMP2 and SOX2 in (A) Huh-7 and (B) HCCLM3 cells were measured by western blotting. The protein levels of (C) p-STAT3, (D) MCL1, (E) MMP2 and (F) SOX2 in subcutaneous tumor tissue were detected by immunohistochemical staining. *P<0.05, **P<0.01 vs. sh-NC. CCT2, chaperonin containing TCP1 subunit 2; sh, short hairpin; NC, negative control; p, phosphorylated; MCL1, myeloid cell leukemia sequence 1; SOX2, SRY-box transcription factor 2.

Article Snippet: The primary antibodies, including p-STAT3 (cat. no. 4113, Cell Signaling Technology), MCL1 (cat. no. 16225-1-AP), MMP2 (cat. no. 10373-2-AP) and SOX2 (cat. no. 11064-1-AP; all Proteintech Group, Inc.), were diluted 1:100 in antibody diluent (cat. no. PR30016; Proteintech Group, Inc.) and applied at 4°C overnight.

Techniques: Knockdown, Activation Assay, Western Blot, Immunohistochemical staining, Staining, Negative Control, Sequencing

Journal: Oncology Reports

Article Title: Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation

doi: 10.3892/or.2026.9086

Article Snippet: The primary antibodies were as follows: CCT2 (cat. no. 24896-1-AP), β-actin (cat. no. 66009-1-Ig), MMP2 (cat. no. 10373-2-AP), myeloid cell leukemia sequence 1 (MCL1; cat. no. 16225-1-AP) and SRY-box transcription factor 2 (SOX2; cat. no. 11064-1-AP; all Proteintech Group, Inc.) and STAT3 (cat. no. 4904) and phosphorylated (p-)STAT3 (Tyr705; cat. no. 4113; both Cell Signaling Technology, Inc.) The membranes were washed three times in TBST (0.1% Tween-20) for 5 min each at room temperature.

Techniques: Knockdown, Activation Assay, Western Blot, Immunohistochemical staining, Staining, Negative Control, Sequencing

Review

mcl1 (Proteintech)

Structured Review

Images

1) Product Images from "Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation"

Related Articles

other:

Blocking Assay:

Incubation:

Similar Products

Image Search Results